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Abstract
Background: Adjuvant therapy for T3N0 rectal cancer was controversial with respect to both radiation and the use
of a combined regimen of chemotherapy. We evaluated both clinical features and biomarkers and sought to
determine risk factors for those patients retrospectively.
Methods: A total of 122 patients with T3N0 rectal cancer were analyzed in this study from January 2000 to
December 2005. Clinicopathologic and biomarkers were used to predict local recurrence (LR), disease-free survival
(DFS), and overall survival (OS).
Results: The median follow-up interval was 45.4 months. Five-year LR, DFS, and OS rates were 10.4%, 68.3%, and
88.7%. Having a lower tumor location and showing low P21 and high CD44v6 expression were identified as risk
factors for LR: patients with two or three of these risk factors had a higher 5-year LR rate (19.3%) than did patients
with none or one of these risk factors (6.8%) (p = 0.05). A poorer DFS was related to low P21 nor high CD44v6
expression but not to tumor location: the 5-year DFS rates were 79.3% for those with neither, 65.9% for those with
either one or the other, and 16.9% for those with both (p = 0.00).
Conclusions: The prognostic model including tumor location, P21 and CD44v6 expressions could help to
distinguish these patients with high risk T3N0 patients and determine whether adjuvant therapy was beneficial.
Introduction
Current guidelines from the National Comprehensive
Cancer Network recommend that all patients with clini-
cal stage II/III rectal cancer should be treated with preo-
perative chemoradiation followed by total mesorectal
excision (TME). However, whether patients with T3N0
rectal cancer, i.e., those with tumors invades through
the muscularis propria into perirectal fasia but no inva-
sion of adjacent organs, and without lymph nodes inva-
sion, should undergo such therapy is still controversial.
It is believed that not all T3N0 patients but those with
high risk patients should be treated. Clinical assessments
of T and N status are mainly based on findings from
clinical examination, supplemented by magnetic
resonance imaging (MRI) and endoscopic ultrasonogra-
phy (EUS). However, this approach has led to over- or
under-staging of disease in approximately 20% of cases,
leading to speculation that those patients may not have
gotten optimal therapy [1,2]. Moreover, the effectiveness
of neoadjuvant chemoradiation therapy in downstaging
disease can cloud the accuracy of disease re-staging [3]-
and T and N status are still considered the strongest
predictors of outcome. The ability to predict which
patients with T3N0 cancer are at the highest risk of
recurrence would be useful for identifying which such
patients are likely to derive the most benefit from adju-
vant therapy and which patients may safely avoid such
therapy, which is associated with adverse effects.
Some investigators have evaluated potential risk fac-
tors with the intent of identifying the best type of adju-
vant therapy for rectal cancer, but unfortunately those
studies were conducted before the advent of total
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the risk of local relapse compared with conventional
surgery [6]. Moreover, there is no prospective rando-
mized trials to compare T3N0 rectal patients who had
TME with adjuvant therapy or not. At present time, it is
not ethical to conduct a prospective randomize clinical
trial to investigate if adjuvant therapy is necessary in
this special group of patients given the evidence of
advantage of neoadjuvant over adjuvant chemoradiation
in the whole stage II/III group of patients. Considering
the existence of uncertainties either in the preoperative
clinical staging or tumor downstaging after effective
neoadjuvant chemoradiation may weaken the power of
outcome driven from trials treated with current stan-
dard neoadjuvant strategy. Therefore, it is important to
identify potential risk factors from patients with post-
TME and with pathologically staged T3N0 disease to
help determine the optimal treatment strategy for indivi-
dual patients. The traditional clinical prognostic and risk
factors have been reported but with no consensus
reached so the combination with some biological factors
would be more helpful. The biological or molecular
markers combined with clinical factors to predict tumor
prognosis have been applied in the guideline of breast
cancer and may have potential value in the future sta-
ging system of colorectal cancer. Predictive value of bio-
markers has been reported in our previous study, which
demonstrated that CD44v6 expression in cancer cells
was a sensitive marker for predicting treatment outcome
in patients with stage II/III rectal cancer after TME [7].
To this end, we evaluated a variety of clinicopathologi-
cal factors and molecular markers in patients with
pathogically staged T3N0 rectal cancer after TME, with
the goal of identifying factors related to predicting
outcome.
Materials and methods
Patient selection
Subjects for this retrospective analysis were selected from
1306 patients with rectal cancer treated with TME at the
Fudan University Cancer Hospital in Shanghai from Janu-
ary 2000 to December 2005. For the present analysis, the
patient selection criteria were as the following: (1) without
any preoperative therapy; (2) undergone TME surgery; (3)
pathologically confirmed T3N0 rectal adenocarcinoma; (4)
no evidence of distant metastases; (5) available to provide
follow-up information at least once. After the medical and
pathologic records were carefully reviewed, 131 patients
with T3N0M0 were selected. Furthermore, only nine cases
out of them received adjuvant radiotherapy because of
beneficial uncertainty. Therefore, these 9 cases were
excluded and a total of 122 patients were identified for our
retrospective analysis.
Immunohistochemical staining for biomarkers
All information on biomarker staining was extracted
from the pathologic records. All dissected tumor speci-
mens were routinely fixed in buffered formalin and
embedded in paraffin. Sections of 4-mm thickness were
stained with hematoxylin-and-eosin for histologic diag-
nosis and then labeled with six primary antibodies: anti-
epidermal growth factor receptor (EGFR) (Clone H11,
code M3563, DAKO; dilution 1:100), anti-P21 (Clone
NCC-RAS-001, code M0637, DAKO; dilution, 1:100),
anti-Her-2 (Clone: PN2A, code M7269, DAKO; dilution
1:400), anti-P53 (Clone: DO-7, code M7001, DAKO;
dilution, 1:50), anti-CD44v6 (Clone: VFF-7, code M0130,
Antibody Diagnostica Inc; dilution 1:50), and anti-prolif-
erating cell nuclear antigen (PCNA) (Clone: PC 10, code
M 0879, DAKO; dilution 1:300). For antigen retrieval,
sections were treated with 10 mM citrate at pH 6.0 in a
750-W microwave oven for three 5-min cycles. The sec-
tions were then immunostained with horseradish peroxi-
dase (HRP) polymer (DAKO) in accordance with the
manufacturer’s specifications. Diaminobenzidine was
used to develop the stains and hematoxylin for the
counterstaining. Negative controls consisted of substitut-
ing normal mouse serum for the primary antibodies.
PCNA staining was expressed as a labeling index of the
percentage of positively staining nuclei among all
counted nuclei. Expression of the other five markers
was quantified by using a visual grading system based
on staining intensity on a scale from 0 to 3. These
scores were routinely included in the pathology reports.
For the purpose of this analysis, we collapsed the scores
into two groupings: low intensity (0 or 1) or high inten-
sity (2 or 3).
Definition of treatment failure
All treatment failures were verified through review of
the medical records. Local-regional failure was defined
as recurrence within the pelvis, including the tumor
bed, regional lymph nodes, anastomosis, or perineal
scar. Distant failure was indicated as disease recurrence
detected in the liver, lung, brain, and other organs out-
side the pelvis.
Statistical analyses
The data used for this analysis included patient age and
sex, distance of the tumor from the anal verge, maxi-
mum tumor diameter, cellular differentiation, the pre-
sence or absence of lymphatic or vascular invasion, the
number of dissected lymph nodes, and whether adjuvant
therapy had been administered. No patients got neoad-
juvant therapy.
Six potential predictive molecular markers (EGFR,
P21, Her-2, P53, CD44v6, and PCNA), detected by
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were also evaluated as potential prognostic factors.
Characteristics were described in terms of frequency
for the categorical variables, means and standard devia-
tions for continuous data, and medians for non-
normally distributed continuous data. Survival time was
calculated from the date of surgery to the date of event
or the last follow-up. Three events were defined: local-
regional failure, disease-specific failure, and death. Data
were censored from patients lost to follow-up, death
from causes other than rectal cancer, or no event as of
the last follow-up. Survival curves were estimated by
using the Kaplan-Meier method and compared with log-
rank tests in the univariate analysis. Cox proportional
hazards regression was used for multivariate modeling
and for examining the prognostic significance of the
variables identified in the models. P values of less than
0.05 were taken to indicate statistically significant
differences.
Results
Clinicopathologic characteristics
Patients’ clinicopathologic characteristics are presented
in Table 1. Sixty-six were men and 56 were women; the
median age was 55 years (range, 27-88 years). Fifty
patients (41.0%) had tumors location ≤ 5c mf r o mt h e
anal verge, and 10 patients (8.2%) had lymphatic or vas-
cular invasion. The median number of lymph nodes
examined was 10 (range, 2-28). All patients had received
5-Fu based adjuvant chemotherapy. All patients had the
detailed records of immunohistochemistry. The distribu-
tion of six molecular markers analyzed was listed in
Table 2.
The median follow-up interval was 45.4 months
(range, 4.2-92.8 months). During the follow-up period,
11 patients developed recurrent disease within the pel-
vis, 25 patients developed distant metastases, and 9
patients died of rectal cancer. The 5-year LR, DFS, and
OS rates for all patients were 10.4%, 68.3%, and 88.7%,
respectively (Figure 1).
Potential risk factors and prognostic significance
All potential risk factors, including clinicopathologic fac-
tors and six molecular biomarkers, were evaluated by
using the Kaplan-Meier method (compared with Log-
rank test). Among six molecular biomarkers, only the
expression level of P21 and CD44v6 exhibited a correla-
tion with prognosis. Significant longer disease-free inter-
val was displayed in patients with high expression of
P21 (79.1% vs. 41.9%, p < 0.05) or low expression of
CD44v6 (75.5% vs. 40.7%, p < 0.05) (Figure 2), and a
tendency of less local relapse (P > 0.05) (Figure 3). For
all clinicopathologic factors, the rectal lesion at a lower
location (the distance from anal verge within 5 cm) and
Table 1 The distribution of clinical pathological factors.
clinico-pathological factors n
Gender
Male 66
Female 56
Age (year)
Mean ± Sd 57 ± 12
Surgery
Lower anterior resection 60
Abdominal perineal resection 66
Distance from anal verge
<= 5 cm 50
>5 cm 72
lymphatic or vascular invasion
Yes 10
No 112
Resected Lymph node number
Median (min-max) 10 (2-28)
Total 122
Table 2 The distribution of molecular markers.
Molecular markers N
P21
-2 8
+2 9
++ 43
+++ 22
CD44/v6
-7 2
+2 7
++ 20
+++ 3
EGFR
-7 1
+2 7
++ 16
+++ 8
Neu
-8 1
+2 6
++ 12
+++ 3
P53
-4 5
+2 7
++ 27
+++ 23
PCNA
<= 50% 32
>50% 90
Total 122
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increased local failure rate compared with the upper
lesion and low-anterior resection in spite of no statisti-
cally significance (Figure 3). None of the other variables
displayed any correlative tendency with OS, DFS or LR
(data not shown). As there wasn’t any factor in our
study showed correlation with OS, we only analyzed
prognostic factors for LR and DFS.
Cox multivariate regression models for predicting LR and
DFS
Four variables-P21 expression level, CD44v6 expression
level, tumor location, and type of surgery-showed effects
on LR (Figure 2). Due to the tumor location and type of
surgery were highly correlated with each other (r = 0.71,
p = 0.00), the type of surgery was excluded from further
analysis. Cox multivariate regression analysis revealed
three factors to be associated with LR: P21, CD44v6,
and tumor location (Table 3). Because the hazard ratios
of these three factors were very close to one another, we
combined these three factors into a prognostic scoring
system, with each of the three unfavorable prognostic
factors allocated 1 point. We then assigned the patients
to one of two risk-of-LR groups according to their score
in this system: low risk (score of 0 or 1) or high risk
(scores of 2 or 3). The 5-year LR rates were significantly
different for the low-risk group (6.8%) and the high-risk
group (19.3%) (p = 0.05, Figure 4).
Different from the LR, tumor location is not the risk
factor of DFS (Table 3). We derived a separate scoring
system for the risk of DFS that was based on only two
variables-expression of P21 and CD44v6. Similar scoring
Figure 1 Local recurrence, disease-free survival, and overall survival rates for all patients.
Figure 2 Disease-free survival rates by P21 and CD44v6 expression levels.
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as c o r eo f“0” was defined as high P21 or low CD44v6
expression, and “1” was low P21 or high CD44v6. Use
of that scoring system led to the identification of three
risk groups: low risk (score of 0), intermediate risk
(score of 1), and high risk (score of 2). The 5-year DFS
rates for these three risk groups were significantly differ-
ent: 79.3% for the low-risk group, 65.9% for the inter-
mediate-risk group, and 16.9% for the high-risk group
(p = 0.00, Figure 5).
Discussion
Our analysis of potential predictors of outcome after
TME for T3N0 rectal cancer revealed that three factors
were associated with a higher risk of LR: the tumor
being located close (≤ 5 cm) to the anal verge, expres-
sing low amounts of P21, and expressing high amounts
of CD44v6. Patients with no or only one risk factor
had a relatively low risk of LR at 5 years (6.8%). In
contrast, the probability of LR in 5 years is high up to
nearly 20% when two or three risk factors were pre-
sents in the high-risk group patients. Thus adjuvant
radiotherapy should be considered for those patients at
high risk of LR according to our scoring system, but
93.2% of those with low-risk disease may benefit from
sparing of treatment induced toxicity with post-opera-
tive radiation.
Other than risk factors with LR, we further found that
two factors were associated with the risk of decreased
DFS: low P21 expression and high CD44v6 expression.
These factors may also be useful in deciding whether a
particular patient should undergo adjuvant therapy or
not. However, further testing of much larger groups of
patients and additional potential prognostic factors are
needed to definitively establish the need, or the role, of
adjuvant therapy for these patients.
Figure 3 Local recurrence rates by tumor location, type of surgery, and P21 and CD44v6 expression levels.
Table 3 the values of b and P in Cox multi-variate regression model for local recurrence and disease-free survival.
b hazard ratio P value
Local recurrence P21 (high:low) 0.591 1.806 0.35
CD44/v6 (low:high) 0.628 1.874 0.36
Tumor location (upper:lower) 0.593 1.809 0.33
Disease-free survival P21 (high:low) 0.925 2.522 0.01
CD44/v6 (low:high) 0.842 2.321 0.03
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represent a different response to clinical treatment.
Gunderson and his colleagues pooled data from five
pre-TME era phase III randomized trials of adjuvant
therapy for rectal cancer and found similar OS and DFS
rates among patients with T3N0 cancer treated with
adjuvant chemotherapy or chemoradiation [8]. These
findings raised concern that trimodality therapy may
have represented overtreatment for some of these
patients.
Other investigators have attempted to identify risk fac-
tors related to outcome for patients with T3N0 rectal
cancer who undergo a conventional radical surgery but
TME procedure was not routinely administrated in their
reports. Clinical factors tested for prognostic value have
included cell differentiation, tumor location, number of
examined lymph nodes, vascular/lymphatic invasion,
and circumferential resection margin status. In one such
analysis of 95 patients with T3N0 rectal cancer at the
Memorial Sloan-Kettering Cancer Center, Merchant et
al. reported that only lymphatic invasion was significant
to predict LR [5]. In another report by Willett et al., his-
tologic type of well to moderately differentiated, tumor
invasion of < 2 mm into the perirectal fat, and without
Figure 4 Local recurrence rates according to the combined prognostic index (P21, CD44v6, and tumor location). High risk involves
having two or three adverse risk factors (low tumor location, low P21 expression, and high CD44v6 expression). Low risk involves having no or
one adverse risk factor.
Figure 5 Disease-free survival rates according to the combined biomarker prognostic index (P21 and CD44v6). High risk involves having
both of the two risk factors: low P21 expression and high CD44v6 expression. Intermediate risk involves having either low P21 expression or
high CD44v6 expression. Low risk involves having neither low P21 expression nor high CD44v6 expression.
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be favorable histologic features [4]. Other risk factors,
such as lower rectal tumor location and inadequate
lymph node dissection, have also been reported [9,10].
However, there are two issues we have to face: firstly, all
these conclusions are drawn from pre-TME studies; sec-
ondly, there are no consistent risk factors confirmed in
these studies. Therefore, these conclusions can’tb e
applied arbitrarily now in TME era.
With appearance of TME surgery, local control and
survival rates have been improved greatly [6]. Several
trials have reported that TME surgery alone can reduce
the local failure rates from 15%-20% to 4%-7% and
improve the survival rate to 80%-85% for patients with
stage II disease [11-14]. Given that patients with more
advanced disease were excluded from these early trials
of TME, the excellent outcome can be largely attributed
to patient selection bias. But, due to the excellent local
control with TME, it also raises the concern of over-
treatment in this intermediate risk group, especially in
T3N0 patients. In our hospital, TME has been routinely
used for rectal cancer patients more than 10 years. It is
the optimal solution to select patients with high risk fac-
tor to be treated as to avoid the possibility of overtreat-
m e n ta f t e rT M E .H o w e v e r ,n oc o n c u r r e n td a t af r o m
randomized trials are available to support the omission
of adjuvant therapy. Our scoring system will be helpful
in treatment decision for T3N0 patients.
On the other hand, apart from clinical characteristics,
the inconsistent conclusion may be partly attributable to
differences in the biological behavior of tumors deter-
mined by intrinsically different molecular regulatory
mechanisms. In our study, a scoring system based on
CD44v6 and P21 expression showed significant prognos-
tic value for both LR and DFS in T3N0 group of
patients which may help to decide treatment
biologically.
CD44v6 is a cell membrane glycoprotein involved in
cell/cell and cell/matrix interactions. Over-expression of
CD44v6 correlates with tumor growth and spread. Some
studies have found increased levels of CD44v6 in tumors
compared with expression in normal tissues [15]. High
CD44v6 expression has been associated with metastatic
disease and a poor prognosis in colorectal cancer
[16-18].
It has also been reported that P21, through interaction
with cyclin-dependent kinases, can induce cell cycle
arrest at the G1/S phase, where cells are insensitive to
radiation-induced DNA damage [19]. In cell line models,
the prognostic value of P21 expression has also been
reported in colon cancer cells [20,21]. Fu et al. specu-
lated that rectal tumors that express P21 expressions
m a yb em o r er a d i o s e n s i t i v et op r e o p e r a t i v er a d i a t i o n
therapy and thus be associated with better prognosis
[22]. Similar results were reported by Havenga et al.
[14]. In another clinical research report, Rau et al. found
that increased P21 expression was associated with
decreased lower proliferative activity after neoadjuvant
chemoradiation [23].
B a s e do no u rd a t as h o w e d ,w ef i n ds o m ec l i n i c a lr i s k
factors as well as biomarker to predict the outcome and
the generated scoring system may help to provide more
tailored therapy in T3N0 patients. Based on the scoring
system that we used, the 5-year LR varied from 19.3% to
6.8% according to risk grouping, suggesting adjuvant
radiation may be benefit in high risk patients with at
least two of the three identified risk factors (low tumor
location, low P21 expression, and high CD44v6 expres-
sion) in decreasing LR.
Our scoring system is also helpful for evaluation the
outcome of DFS which may be more associated with
adjuvant chemotherapy other than radiation. In terms of
adjuvant chemotherapy, the regimen for rectal cancer
w a se x t r a p o l a t e df r o mt h a tf o rc o l o nc a n c e re v e n
though there is no definitive evidence to clarify they are
the same disease. Chemotherapy is also indicated in
high risk stage II patients and the chemotherapy regi-
men in stage II patients is not as uniform as with stage
III patients. In stage II colon cancer, the MOSIC rando-
mized phase III trial has showed the similar results of 5-
year DFS rates with intensive (FOLFOX) to conventional
(5-FU/LV) chemotherapy regimen (83.7% vs 79.9% p =
0.258), suggesting that the possibility of sparing more
intensive treatment in stage II colon cancer patients.
There is no data to illustrate if more aggressive treat-
ment will be benefit when result of stage II colon cancer
derived into rectal cancer with same staging. Our scor-
ing system showed significant difference of 5-year DFS
of 16.9% to 79.3% with high and low score T3N0
patients and suggested a more aggressive chemotherapy
may be appropriate for this group of rectal cancer
patients with high score.
Therefore, we conclude that the scoring system we
developed in this study may be useful for identifying
whether patients could be benefit from adjuvant therapy
after TME for T3N0 rectal cancer or not. On the basis
of our results, we suggest that adjuvant radiotherapy is
required for high-risk patients, and that a more aggres-
sive chemotherapy regimen should be recommended in
the patients with increased risk scores. Molecular mar-
kers tested in the pre-treatment biopsy tissue may be
helpful for selecting patients with potential high risk of
recurrence. Such study has been reported in 30 patients
from German CAO/ARO/AIO-94 rectal cancer study.
There were 54 genes found to be different between
responder and non-responders of neoadjuvant chemora-
diation in 23 patients. This may suggest the potential
possibility in decision making with molecular markers
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been in the status of exploration and there is no consen-
sus reached for specific gene expression so far. We have
undergoing a perspective study in locally advance rectal
cancer patients which is exploring the molecular mar-
kers which may be radiosensitive and radioresistant to
select patients more suitable for neoadjuvant chemora-
diation. So, we will combine clinical features and mole-
cular markers in our ongoing study. In the future,
further prospective randomized trials will be focused on
investigating the optimal treatment strategy in stage II
(T3N0) rectal cancer. Our scoring system will provide a
basic reference as well as pretreatment molecular mar-
kers for future study in this group of patients.
Conclusions
In conclusion, we propose that the scoring system
including tumor location, P21 and CD44v6 expressions
could help to distinguish these patients with high risk
T3N0 patients and determine whether adjuvant therapy
was beneficial. The optimal treatment strategy in T3N0
rectal cancer will be investigated in the future studies.
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